Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions, designed to cover most typical lab tests with a smaller footprint ...
Michael Iskra, executive vice president of commercial excellence and strategy at Ortho, said his company is focused on delivering quality results and the operational financial impacts of diagnostic ...
Assay is now commercially available in the U.S. and countries accepting CE Mark RARITAN, New Jersey, March 8, 2018 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, ...
RARITAN, N.J., July 22, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its VITROS (R) ...
RARITAN, N.J., July 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO ...
RARITAN, N.J.- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced CE Mark for its next-generation VITROS® High Sensitivity Troponin I assay. This new assay is the latest ...
- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians ...
RARITAN, New Jersey and SINGAPORE, May 14, 2019 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, in collaboration with Singapore Management University, will host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results